Clinical Trial: Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal (SEB) Cell Carcinomas in

Brief Summary: Multicenter, double-blind, randomized, vehicle-controlled evaluates the efficacy and safety of patidegib gel, 2% and 4% in comparison with vehicle in subjects at least 18 years of age that meet the diagnostic criteria for basal cell nevus syndrome (BCNS). Subjects will be randomized to receive patidegib gel 4%, patidegib gel 2%, or the vehicle gel for a 26 week treatment period.